Phio Pharmaceuticals Corp. (NASDAQ:PHIO – Get Free Report) dropped 5% during trading on Thursday . The stock traded as low as $1.89 and last traded at $2.09. Approximately 370,047 shares were traded during trading, an increase of 217% from the average daily volume of 116,627 shares. The stock had previously closed at $2.20.
Phio Pharmaceuticals Trading Down 7.7 %
The business’s 50 day moving average price is $2.68 and its two-hundred day moving average price is $3.48. The company has a market capitalization of $2.04 million, a price-to-earnings ratio of -0.18 and a beta of 1.49.
About Phio Pharmaceuticals
Phio Pharmaceuticals Corp. engages in the development of immuno-oncology therapeutics in the United States. The company is developing PH-762, an INTASYL compound in Phase 1b dose-escalating clinical trials to reduce the expression of cell death protein 1 (PD-1), a protein that inhibits T cells’ ability to kill cancer cells; and PH-762 treated double positive tumor infiltrating lymphocytes, which is in Phase 1 clinical trials to treat advanced melanoma and other advanced solid tumors.
Further Reading
- Five stocks we like better than Phio Pharmaceuticals
- Stock Analyst Ratings and Canadian Analyst Ratings
- Buffett Takes the Bait; Berkshire Buys More Oxy in December
- REIT Stocks – Best REIT Stocks to Add to Your Portfolio Today
- Top 3 ETFs to Hedge Against Inflation in 2025
- Utilities Stocks Explained – How and Why to Invest in Utilities
- These 3 Chip Stock Kings Are Still Buys for 2025
Receive News & Ratings for Phio Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Phio Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
